Overexpression Of ASAP1 Is Associated With Clinicopathologic Features And Decreased Survival In Patients With Pancreatic Carcinoma

ObjectiveTo detect the expression of AS AP1 in pancreatic carcinoma tissue specimens,and to analyze the effect of ASAP1 on the survival in patients with primary pancreatic carcinoma.MethodsThe protein expression of AS AP1 was detected by immunohistochemistry methods in 96 pancreatic carcinoma tissues. We analyzed the association between immunohistochemically detected ASAP1 expression in pancreatic carcinoma and clinicopathologic characteristics. Survival curves were completed using the Kaplan-Meier method and compared using log-rank analysis.ResultsThe immunohistochemical results showed that Immunostaining for ASAP1 was expressed in 78 cases (81.2%). The positive expression was in the cytoplasm and the lumen of edge with buffy or brownish yellow. Atypical hyperplasia and highly differentiated tissue cells were stained strongly,but low differentiation was relatively poor. The positive expression of AS AP1 was positively correlated with clinical stage (P < 0.05). From the clinical stage I to IV, the expression of ASAP1 was increased, and then decreased. The expression of ASAP1 was the most in the II stage, and showed a continuous downward trend in the III and IV stage. Tumors with negative expression of ASAP1 had a survival advantage compared with tumors that had positive expression of ASAP1(P<0.01).ConclusionThe expression of ASAP1 in pancreatic carcinoma tissue is related to the clinical stage and the prognosis of pancreatic carcinoma. Which can be used as an assessment of the prognosis of patients with pancreatic carcinoma. This study is expected to provide a theoretical basis for the prevention and treatment of pancreatic cancer, in particular, to explore the feasibility of ASAP 1 gene therapy for pancreatic cancer.